SARS-CoV-2 genome publicly shared Jan 11 2020 via GISAID; BioNTech Project Lightspeed launched Jan 27 2020

On January 11, 2020, the SARS-CoV-2 genome was first publicly shared via GISAID, hosting submissions from the Chinese CDC. Within two weeks — on January 27, 2020 — BioNTech launched Project Lightspeed using the publicly available genome (S-0039).

The fact pair is the empirical anchor for the §6.2 distinction between the technology of GISAID (which worked at the highest stakes infectious-disease moment of the decade) and the governance of GISAID (which subsequently produced the access suspensions and feed terminations documented in E-0025). The 16-day interval between public sharing and a major mRNA vaccine programme launch demonstrates that the genomic-surveillance protocol delivered exactly the resilience and access properties its design promised.

C-0028's "adversarial governance" reading depends on this evidence: the failures it documents (access suspensions, terminated feeds, Open Access revocation) are governance failures of the same platform whose technology made the COVID-19 response possible. Without this empirical anchor, the GISAID critique reduces to "the platform was bad," which is not the architectural argument the section makes. The argument is that the technology worked and the governance determined whether the technology continued to work — which requires both halves of the GISAID record to be in evidence.